Grupo de Transformación y Metástasis

Eva González Suárez Jefe de Grupo
T +34 (+34) 917 328 000 (Ext 3550)
egonzalez@cnio.es

Investigadores

Patricia González
María Jiménez
Gema Pérez

Becarios Pre-Doctorales

Alexandra Barranco
Marina Císcar
Alejandro Collado
Pedro Luis Echevarria
Jaime Redondo
Sergi Velasco

Técnicos de Laboratorio

Víctor López

Research in the Transformation and Metastasis Group aims to identify novel therapeutic targets for epithelial cancer treatment and to elucidate resistance mechanisms to drugs currently available. Tumours exploit and manipulate for their benefit the same mechanisms that work correctly in the healthy tissue. Thus, we first aim to understand normal development, and then to identify the key events that lead to tumour initiation, progression and metastasis developed in order to avoid and combat them. Complementary tools including primary cell cultures and organoids, mouse models and clinical samples are used with the final goal of translating basic knowledge into clinically relevant findings.

One of our research lines aims to characterise the role of the TNF family member RANK in mammary gland development and breast cancer and to elucidate its therapeutic potential.

Publicaciones

Bernat-Peguera A, Navarro-Ventura J, Lorenzo-Sanz L, da Silva-Diz V, Bosio M, Palomero L, Penin RM, Pérez Sidelnikova D, Bermejo JO, Taberna M, Vilariño N, Piulats JM, Mesia R, Viñals JM, González-Suárez E, Capella-Gutierrez S, Villanueva A, Viñals F, Muñoz P. (2021). FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma. Clin Cancer Res 27, 1491-1504. Publicación CNIO.
Gómez-Aleza C, González-Suárez E (2021). Inhibition of RANK signaling as a potential immunotherapy in breast cancer. Oncoimmunology 10, 1923156. Publicación CNIO.
Benítez S, Cordero A, Santamaría PG, Redondo-Pedraza J, Rocha AS, Collado-Solé A, Jimenez M, Sanz-Moreno A, Yoldi G, Santos JC, De Benedictis I, Gómez-Aleza C, Da Silva-Álvarez S, Troulé K, Gómez-López G, Alcazar N, Palmero I, Collado M, Serrano M, Gonzalez-Suarez E (2021). RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness.. Dev Cell 56, 1727-1741. Publicación CNIO.
Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA 2nd, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH; PDXNET Consortium; EurOPDX Consortium. (2021). Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53, 86-99. Publicación CNIO.
Sanz-Moreno A, Palomeras S, Pedersen K, Morancho B, Pascual T, Galván P, Benítez S, Gomez-Miragaya J, Ciscar M, Jimenez M, Pernas S, Petit A, Soler-Monsó MT, Viñas G, Alsaleem M, Rakha EA, Green AR, Santamaria PG, Mulder C, Lemeer S, Arribas J, Prat A, Puig T, Gonzalez-Suarez E. (2021). RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cance. Breast Cancer Res 23, 42. Publicación CNIO.
Gómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, Maetens M, Salgado R, Zafeiroglou M, Pellegrini P, Venet D, Garaud S, Trinidad EM, Benítez S, Vuylsteke P, Polastro L, Wildiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothé F, Willard-Gallo K, Michiels S, Muñoz P, Walzer T, Planelles L, Penninger J, Azim HA Jr, Loi S, Piccart M, Sotiriou C, González-Suárez E (2020). Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells.. Nat Commun 11, 6335. Publicación CNIO. Open Access
Gómez-Miragaya J, Morán S, Calleja-Cervantes ME, Collado-Solé A, Paré L, Gómez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A, Eroles P, Prat A, Esteller M, González-Suárez E. (2019). The altered transcriptome and DNA methylation profiles of docetaxel resistance in breast cancer PDX models.. Mol Cancer Res 17, 2063-2076. Publicación en otras instituciones.
Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E (2019). Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.. Cancer Res 79, 4258-4270. Publicación en otras instituciones.
von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body JJ. (2019). Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.. Cancer Treat Rev 76, 57-67. Publicación en otras instituciones.
Bernat-Peguera A, Simón-Extremera P, da Silva-Diz V, López de Munain M, Díaz-Gil L, Penin RM, González-Suárez E, Pérez Sidelnikova D, Bermejo O, Viñals JM, Viñals F, Muñoz P. (2019). PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma.. Oncogene 38, 5021-5037. Publicación en otras instituciones.
Piqué L, Martinez de Paz A, Piñeyro D, Martínez-Cardús A, Castro de Moura M, Llinàs-Arias P, Setien F, Gomez-Miragaya J, Gonzalez-Suarez E, Sigurdsson S, Jonasson JG, Villanueva A, Vidal A, Davalos V, Esteller M (2019). Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer.. Oncogene 38, 7106-7112. Publicación en otras instituciones.
Cánovas B, Igea A, Sartori AA, Gomis RR, Paull TT, Isoda M, Pérez-Montoyo H, Serra V, González-Suárez E, Stracker TH, Nebreda AR (2018). Targeting p38a Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells.. Cancer Cell 33, 1094-1110. Publicación en otras instituciones.
Koledova Z, Howard BA, Englund J, Bach K, Bentires-Alj M, Gonzalez-Suarez E (2018). European Network of Breast Development and Cancer turned 10 years: a growing family of mammary gland researchers.. Breast Cancer Res 20, 102. Publicación en otras instituciones.
Ruiz de Garibay G, Herranz C, Llorente A, Boni J, Serra-Musach J, Mateo F, Aguilar H, Gómez-Baldó L, Petit A, Vidal A, Climent F, Hernández-Losa J, Cordero Á, González-Suárez E, Sánchez-Mut JV, Esteller M, Llatjós R, Varela M, López JI, García N, Extremera AI, Gumà A, Ortega R, Plà MJ, Fernández A, Pernas S, Falo C, Morilla I, Campos M, Gil M, Román A, Molina-Molina M, Ussetti P, Laporta R, Valenzuela C, Ancochea J, Xaubet A, Casanova Á, Pujana MA. (2018). Correction: Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness.. PLoS One 13, e0207586. Publicación en otras instituciones.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L (2017). Interrogating open issues in cancer medicine with patient-derived xenografts.. Nat Rev Cancer 17, 632. Publicación en otras instituciones.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L (2017). Interrogating open issues in cancer precision medicine with patient-derived xenografts.. Nat Rev Cancer 17, 254-268. Publicación en otras instituciones.
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA (2017). Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.. Oncogene 36, 2737-2749. Publicación en otras instituciones.
Gómez-Miragaya J, Palafox M, Paré L, Yoldi G, Ferrer I, Vila S, Galván P, Pellegrini P, Pérez-Montoyo H, Igea A, Muñoz P, Esteller M, Nebreda AR, Urruticoechea A, Morilla I, Pernas S, Climent F, Soler-Monso MT, Petit A, Serra V, Prat A, González-Suárez E (2017). Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.. Stem Cell Reports 8, 1392-1407. Publicación en otras instituciones.
Pérez-Salvia M, Simó-Riudalbas L, Llinàs-Arias P, Roa L, Setien F, Soler M, de Moura MC, Bradner JE, Gonzalez-Suarez E, Moutinho C, Esteller M. (2017). Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer.. Oncotarget 8, 51621-51629. Publicación en otras instituciones.
Gomez-Miragaya J, González-Suárez E (2017). Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer.. Mol Cell Oncol 4, e1338208. Publicación en otras instituciones.